Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 12, 1998, Pages 3123-3129

  Miller, Veronica ^a,d   De Béthune, Marie Pierre ^b   Kober, Astrid ^a   Stürmer, Martin ^a   Hertogs, Kurt ^b   Pauwels, Rudi ^b   Stoffels, Paul ^b,c   Staszewski, Schlomo ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Virco BVBA   (Belgium)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOVIRIDE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TALVIRALINE; TIVIRAPINE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROSS RESISTANCE; ENZYME INHIBITION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STRAIN DIFFERENCE; VIRUS INFECTION;

EID: 0345486993     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.12.3123     Document Type: Article

References (47)

1. Bacheler, L. T., E. Anton, D. Baker, B. Cordova, W. Fiske, S. Garber, K. Logue, C. Rizzo, R. Tritch, and S. Erickson-Viitanen. 1997. Impact of mutation, plasma protein binding and pharmacokinetics on clinical efficacy of the HIV-1 nonnucleoside reverse transcriptase inhibitor DMP 266, abstr. I-115, p. 38. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
2. Bacheler, L. T., H. George, G. Hollis, K. Abremski, and The SUSTIVA Resistance Study Team. 1998. Resistance to Efavirenz (SUSTIVA) in vivo, abstr. 703, p. 56. In Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
3. Bacolla, A., C. K. Shih, J. M. Rose, G. Piras, T. C. Warren, C. A. Grygon, R. H. Ingraham, R. C. Cousins, D. J. Greenwood, D. Richman, Y. C. Cheng, and J. A. Griffin. 1993. Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. J. Biol. Chem. 268:16571-16577.
4. Boyer, P. L., H. Q. Gao, and S. H. Hughes. 1998. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob. Agents Chemother. 42:447-452.
5. Buckheit, R. W., J. Germany-Decker, M. G. Hollingshead, L. B. Allen, W. M. Shannon, P. A. J. Janssen, and M. A. Chirigos. 1993 Differential antiviral activity of two TIBO derivatives against the human immunodeficiency and murine leukemia viruses alone and in combination with other anti-HIV agents. AIDS Res. Hum. Retroviruses 9:1097-1106.
6. CAESAR Coordinating Committee. 1997. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 349:1413-1421.
7. Das, K., J. Ding, Y. Hsiou, A. D. Clark, Jr., H. Moereels, L. Koymans, K. Andries, R. Pauwels, P. A. Janssen, P. L. Boyer, P. Clark, R. H. Smith, Jr., M. B. Kroeger Smith, C. J. Michejda, S. H. Hughes, and E. Arnold. 1996. Crystal structures of 8-C1 and 9-C1 TIBO complexed with wild-type HIV-1 RT and 8-C1 TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J. Mol. Biol. 264:1085-1100.
8. Davey, R. T., D. G. Chiatt, G. F. Reed, W. W. Freimuth, B. R. Herpin, J. A. Metcalf, P. S. Eastman, J. Falloon, J. A. Kovacs, M. A. Polis, R. E. Walker, H. Masur, J. Boyle, S. Coleman, S. R. Cox, L. Wathen, C. L. Daenzer, and H. C. Lane. 1996. Randomized, controlled phase I/II trial of combination therapy with delavirdine and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 40: 1657-1664.
9. De Jong, M. D., D. R. Shuurman, J. M. A. Lange, and C. A. B. Boucher. 1996. Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective pressure. Antiviral Ther. 1:33-41.
10. Demeter, L. M., P. M. Meehan, G. Morse, P. Gerondelis, A. Dexter, L. Berrios, S. Cox, W. Freimuth, and R. C. Reichman. 1997. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 14:136-144.
11. Descamps, D., I. Loussert-Ajaka, G. Collin, D. Candotti, O. Bouchaud, S. Sargosti, F. Simon, and F. Brun-Vézinet. 1996. Susceptibility of HIV-1 group O to antiretroviral agents, abstr. 13, p. 7. In Program and abstracts of the 5th International Workshop on HIV Drug Resistance.
12. Dueweke, T. J., T. Pushkarskaya, S. M. Poppe, S. M. Swaney, J. Q. Zhao, I. S. Y. Chen, M. Stevenson, and W. G. Tarpley. 1993. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistance human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 90:4713-4717.
13. Hertogs, K., M. P. De Bèthune, V. Miller, T. Ivens, P. Schel, A. Van Canwenberge, C. Van Den Eynde, V. Van Gerwen, H. Azijn, M. Van Houtte, F. Peeters, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
14. Hicks, C., D. Haas, D. Seekins, R. Cooper, J. Gallant, M. Mileno, N. M. Ruiz, D. J. Manion, L. M. Ploughman, D. F. Labriola, and The Dupont Merck Pharmaceutical Company Clinical Development Team. 1997. A phase II, double-blind, placebo-controlled, dose-ranging study to assess the antiretroviral activity and safety of efavirenz (DMP 266) in combination with open-label zidovudine, abstr. 920, p. 5. In Abstracts-Latebreaker Program of the 6th European Conference on Clinical Aspects and Treatment of HIV-Infection.
15. Hsiou, Y., K. Das, J. Ding, A. D. Clark, Jr., P. L. Boyer, P. A. J. Janssen, J. P. Kleim, M. Rösner, S. H. Hughes, and E. Arnold. 1998. Crystal structures of wild-type and mutant HIV-1 reverse transcriptase and nonnucleoside inhibitors: implications for drug resistance mechanisms, ahstr. 21, p. 17. In Programs and abstracts of the 2nd International Workshop on HIV Drug resistance and Treatment Strategies.
16. Imrie, A., A. Beveridge, W. Genn, J. Vizzard, D. A. Cooper, and The Sydney Primary HIV Infection Study Group. 1997. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. J. Infect Dis. 175:1502-1506.
17. Jeffrey, S., D. Baker, R. Tritch, C. Rizzo, K. Logue, and L. Bacheler. 1998. A resistance and cross resistance profile for SUSTIVA (efavirenz, DMP 266), abstract 702. In 5th Conference on Retroviruses and Opportunistic Infections.
18. Kleim, J. P., R. Bender, R. Kirsch, C. Meichsner, A. Paessens, M. Rösner, H. Rübsamen-Waigmann, R. Kaiser, M. Wichers, K. E. Schneweis, I. Winkler, and G. Reiss. 1995. Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 39:2253-2257.
19. Kleim, J. P., R. Bender, R. Kirsch, et al. 1994. Mutational analysis of residue 190 of HIV-1 reverse transcriptase. Virology 200:696-701.
20. Koup, R. A., V. J. Merluzzi, K. D. Hargrave, et al. 1991. Inhibition of HIV-1 replication by the dipyridodiazepinone BI-RG-587. J. Infect Dis 161:966-970.
21. Larder, B. A., A. Kohli, S. Bloor, S. D. Kemp, P. R. Harrigan, R. T. Schooley, J. M. A. Lange, K. N. Pennington, M. H. St. Clair, and The Protocol 34,225-02 Collaborative Group. 1996. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2′,3′-dideoxyinosine or AZT plus 2′,3′-dideoxycytidine combination therapy. J. Virol. 70:5922-5929.
22. Miller, V., A. Phillips, C. Rottmann, S. Staszewski, R. Pauwels, K. Hertogs, M. P. De Bèthune, S. D. Kemp, S. Bloor, P. R. Harrigan, and B. A. Larder. 1998. Dual resistance to zidovudine (ZDV) and lamivudine (3TC) in patients treated with ZDV/3TC combination therapy: association with therapy failure. J. Infect. Dis. 177:1521-1532.
23. Moeremans, M., M. De Raeymaeker, R. Van den Broeck, P. Stoffels, M. De Brabander, J. De Cree, K. Hertogs, R. Pauwels, S. Staszewski, and K. Andries. 1995. Virological analysis of HIV-1 isolates in patients treated with the non-nucleoside reverse transcriptase inhibitor R091767, (-)-(S)-8-chloro-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1-jk] [1,4]benzodiazepine-2(1H)-thione monohydrochloride (8-chloro-TIBO), abstr. 38, p. 33. In Programs and abstracts of the 4th International Workshop on HIV Drug Resistance.
24. Montaner, J. S. G., P. Reiss, D. Cooper, S. Vella, M. Harris, B. Conway, M. A. Wainberg, D. Smith, P. Robinson, D. Hall, M. Myers, and J. M. A. Lang for The INCAS Study Group. 1998. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. JAMA 279:930-937.
25. Murphy, R. L., and J. Montaner. 1996. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp. Opin. Invest. Drugs 5:1183-1199.
26. Nájera, I., A. Holguín, M. E. Quinones-Mateu, M. Á. Muñoz-Fernández, R. Nájera, C. López-Galíndez, and E. Domingo. 1995. pol gene quasispecies of human immunodeficiency virus mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. 69:23-31.
27. Nijhuis, M., N. Back, D. de Jong, W. Keulen, R. Schuurman, B. Berkhout, and C. Boucher. 1996. Host cell-dependent replication efficacy of 3TC-resistant HlV-1 variants, abstr. 86, p. 54. In Program and abstracts of the 5th International Workshop on HIV Drug Resistance.
28. Pauwels, R., K. Andries, J. Desmyter, et al. 1990. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343:470-473.
29. Pauwels, R., K. Andries, Z. Debyser, et al. 1993. Potent and highly selective human immunodeficiency virus type 1 inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:1711-1715.
30. Pauwels, R., K. Andries, Z. Debyser, M. J. Kukla, D. Schols, H. J. Breslin, R. Woestenborghs, J. Desmyter, M. A. C. Janssen, E. De Clercq, and P. A. J. Janssen. 1994. New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs. Antimicrob. Agents Chemother. 38:2863-2870.
31. Richman, D., C. K. Shih, I. Lowy, et al. 1991. HIV-1 mutants resistant to nonnucleoside reverse transcriptase inhibitors arise in tissue culture. Proc. Natl. Acad. Sci. USA 88:11241-11245.
32. Richman, D., A. S. Rosenthal, M. Skoog, R. J. Eckner, T.-C. Chou, J. P. Sabo, and V. Merlazzio. 1991. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob. Agents Chemother. 35:305-308.
33. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Panletti, C.-K. Shin, M. Myers, and J. Griffin. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666.
34. Rozenbaum, W., and The AVANTI Study Group. 1997. AVANTI 1. A randomized, double-blind, comparative trial to evaluate the efficacy, safety and tolerance of combination antiretroviral regimens for the treatment of HIV-1 infection: AZT/3TC versus AZT/3TC/loviride in antiretroviral naive patients, abstr. 368, p. 132. In Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections.
35. Rübsamen-Waigmann, H., M. A. Waigmann, E. Huquenel, A. Shah, A. Paessens, J. P. Kleim, and M. Rosner. 1996. Antiviral profile of HBY-097, a nonnucleoside inhibitor of HIV-1 RT in a phase I study, abstr. Mo. A. 1102. In XI International Conference on AIDS.
36. Ruiz, N. M., D. J. Manion, D. F. Labriola, P. A. Friedman, K. J. Gorelick, E. B. Faulkner, A. P. Goldberg, and The DMP 266 Development Team. 1997. HIV-1 suppression to "<1 copy/mL" (OD = background) by Amplicor assay in patients receiving indinavir +/-DMP 266 (efavirenz). Results of DMP 266-003, cohort IV, abstr. 921, p. 5. In Abstracts - Latebreaker Program of the 6th European Conference on Clinical Aspects and Treatment of HIV-Infection.
37. Salzman, N. K., H. C. Lane, C. Chappey, H. Imamichi, and Y. M. Zhaog. 1996. Patterns of HIV drug resistance during combined or monotherapy with delavirdine, abstr. 51, p. 32. In Program and abstracts of the 5th International Workshop on HIV Drug Resistance.
38. Shah, A., K. Kumor, J. Sullivan, R. Amand, S. Cole, V. Agarwal, G. Krol, E. Huguenel, J. R. Suarez, and A. H. Heller. 1996. Safety, tolerability and pharmacokinetics of HBY-097 in asymptomatic and mildly symptomatic HIV positive patients, abstr. Mo. B. 1326. In XI International Conference on AIDS.
39. Spence, R. A., W. M. Kati, K. S. Anderson, and K. A. Johnson. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267:988-993.
40. Staszewski, S., V. Miller, A. Kober, R. Colebunders, B. Vandercam, J. Delescluse, N. Clumeck, F. Van Wanzeele, M. De Brabander, J. De Creè, M. Moeremans, K. Andries, C. Boucher, P. Stoffels, P. A. J. Janssen, and members of The Loviride Collaborative Study Group. 1996. Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Antiviral Ther. 1:42-50.
41. Staszewski, S., V. Miller, S. Rehmet, T. Stark, J. De Creè, M. De Brabander, M. Peeters, K. Andries, M. Moeremans, M. De Raeymaeker, G. Pearce, R. Van Den Broeck, W. Verbiest, and P. Stoffels. 1996. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS 10:F1-F7.
42. Tantillo, C., J. Ding, A. Jacobo-Molina, et al. 1994. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase inhibitors. J. Mol. Biol. 243:369-387.
43. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
44. Wakefield, J. K., S. A. Jablonski, and C. D. Morrow. 1992. In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome. J. Virol. 66:6806-6812.
45. Winslow, D. L., S. Garber, C. Reid, H. Scarnati, D. Baker, M. M. Rayner, and E. D. Anton. 1996. Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. AIDS 10:1205-1209.
46. Young, S. D., S. F. Britcher, L. O. Tran, L. S. Payne, W. C. Lumma, T. A. Lyle, J. R. Huff, P. S. Anderson, D. B. Olsen, S. S. Carroll, D. J. Pettibone, J. A. O'Brien, R. G. Ball, S. K. Balani, J. H. Lin, I.-W. Chen, W. A. Schleif, V. V. Sardana, W. J. Long, V. W. Byrnes, and E. A. Emini. 1995. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39:2602-2605.
47. Zennou, V., F. Mammano, S. Paulous, D. Mathez, and F. Clavel. 1998. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72:3300-3306.